Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
07/2012
07/17/2012US8221788 Pharmaceutical compositions containing rosuvastatin calcium
07/17/2012US8221787 Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production
07/17/2012US8221786 Pharmaceutical formulations containing an SGLT2 inhibitor
07/17/2012US8221785 Transdermal hormone delivery system: compositions and methods
07/17/2012US8221784 Transdermal hormone delivery system: compositions and methods
07/17/2012US8221783 Medical devices with triggerable bioadhesive material
07/17/2012US8221779 Compositions and methods for the delivery of poorly water soluble drugs and methods of treatment
07/17/2012US8221777 Structurally modified acellular tissue engineering scaffolds and methods of production
07/17/2012US8221774 Lotioned wipe product to reduce adhesion of soils or exudates to the skin
07/17/2012US8221773 Hydrogels and uses thereof
07/17/2012US8221772 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, palmitic acid or polypeptide comprising lysine or arginine; cysteine or leucine; sodium chloride osmotic agent; aerosol drug delivery; respiratory system disorders; antisecretory and antiinflammatory agents
07/17/2012US8221771 Formulations containing an immune response modifier
07/17/2012US8221763 Yeast-antigen compositions and methods of using the same
07/17/2012US8221747 Stable pancreatic enzyme compositions
07/17/2012US8221734 Self-heating shaving compositions
07/17/2012US8221536 Cosmetic comprising multi-colored lustrous pearlescent pigments
07/17/2012US8221395 Method and apparatus for automatically modifying delivery profile of drug delivery system
07/17/2012CA2706264C Propofol transparent anesthetic solution, with low venous irritation threshold
07/17/2012CA2682638C Pharmaceutical composition comprising (2r, 3s, 4r, 5r)-5-(4-amino-2-oxo-2h-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl isobutyrate
07/17/2012CA2666492C Stable polypeptide formulations
07/17/2012CA2659917C Encapsulated vaccines for the oral vaccination and boostering of fish and other animals
07/17/2012CA2651445C Solid medicament dosage form consumption aid
07/17/2012CA2620341C Sanitary napkins with hydrophobic lotions
07/17/2012CA2579882C Edible vaccine
07/17/2012CA2559250C X-ray visible drug delivery device
07/17/2012CA2542049C Finely particulate composite containing carbon compound encapsulated therein
07/17/2012CA2540235C Pharmaceutical use of a composition containing fenofibrate
07/17/2012CA2539303C Device and method for making particles
07/17/2012CA2517372C Pharmaceutical composition of alendronic acid, salts or esters thereof, and a process for its preparation
07/17/2012CA2515006C Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
07/17/2012CA2505520C Protein-stabilized liposomal formulations of pharmaceutical agents
07/17/2012CA2502437C Method and composition containing latanoprost for treating ocular hypertension and glaucoma
07/17/2012CA2496699C Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
07/17/2012CA2487968C A novel drug dosing regimen
07/17/2012CA2477217C Topical dapsone for the treatment of acne
07/17/2012CA2457248C Applicators, dispensers and methods for dispensing and applying adhesive material
07/17/2012CA2436416C Compositions of aminoalkyl methacrylate copolymer e and dissolution modifying excipients for preparing capsules by injection moulding
07/17/2012CA2418984C Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof
07/17/2012CA2395882C Proteoliposomes containing an integral membrane protein having one or more transmembrane domains
07/14/2012CA2727997A1 Herbal solid formulation and process for preparing the same
07/14/2012CA2727995A1 Herbal solid formulation and process for preparing the same
07/14/2012CA2727990A1 Herbal solid formulation and process for preparing the same
07/12/2012WO2012094679A2 Compositions and methods for delivery of high-affinity oxygen binding agents to tumors
07/12/2012WO2012094653A2 Compositions and methods for macromolecular drug delivery
07/12/2012WO2012094598A2 Pharmaceutical compositions of iron for oral administration
07/12/2012WO2012094574A2 Stabilized polyribonucleotide nanoparticles
07/12/2012WO2012094541A2 Acoustically responsive particles with decreased cavitation threshold
07/12/2012WO2012094381A2 Spray drying vancomycin
07/12/2012WO2012094360A2 Biotherapeutics for the treatment of infectious diseases
07/12/2012WO2012094304A1 Nanotubes as carriers of nucleic acids into cells
07/12/2012WO2012094302A2 Drug delivery using fine fiber encapsulation
07/12/2012WO2012094293A1 Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
07/12/2012WO2012094283A2 Bepotastine compositions
07/12/2012WO2012094033A1 Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
07/12/2012WO2012094020A1 Methods and compositions for delivery of taxanes in stable oil-in-water emulsions
07/12/2012WO2012094010A1 Compositions and methods of aloe polysaccharides
07/12/2012WO2012093980A1 Improved risedronate formulation
07/12/2012WO2012093979A1 Water-soluble dosage forms comprising ibandronate
07/12/2012WO2012093978A1 Effervescent bisphosphonate formulations
07/12/2012WO2012093977A1 Water soluble pharmaceutical formulations comprising ibandronate and an inorganic salt for use in treatment of bone diseases
07/12/2012WO2012093976A1 A composition comprising ibandronate at least 50 % of a filling agent and a sweetener
07/12/2012WO2012093975A1 Water soluble formulations comprising ibandronate sodium with a water content less than 11 % by weight
07/12/2012WO2012093974A1 Improved bisphosphonate formulations
07/12/2012WO2012093973A2 Stable acarbose formulations
07/12/2012WO2012093972A1 Water soluble dosage forms
07/12/2012WO2012093971A2 Effervescent compositions comprising amlodipine
07/12/2012WO2012093647A1 Solution for treatment of bacterial disease in animals and plants by reishi kazuno extract and production method therefor
07/12/2012WO2012093524A1 Oil-in-water emulsion composition
07/12/2012WO2012093505A1 Composition for adhesive hydrogel and use thereof
07/12/2012WO2012093404A2 Parenteral formulations of levosimendan
07/12/2012WO2012093252A1 Pharmaceutical composition
07/12/2012WO2012093171A1 Method for preparing aqueous pharmaceutical suspensions including a drug that is effective in treating rhinitis
07/12/2012WO2012093161A1 Immunosuppressant formulations
07/12/2012WO2012093137A1 Liposome formulation suitable for treating or preventing tuberculosis
07/12/2012WO2012093117A1 Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
07/12/2012WO2012093113A1 O/w-emulsions comprising semifluorinated alkanes
07/12/2012WO2012092990A2 Medical product for improving the ability of a mammal to conceive
07/12/2012WO2012092865A1 Cationic polymers formed from amino group-bearing monomers and heterocyclic linkers
07/12/2012WO2012092718A1 Photo-responsive supramolecular hydrogels
07/12/2012WO2012092712A1 Lyophilized nanometer particle powder preparation comprising recombinant albumin prepared from human plasma
07/12/2012WO2012068516A3 Low dose cannabinoid medicaments
07/12/2012WO2012058464A3 Multiphasic polymeric particles capable of shape-shifting via environmental stimulation
07/12/2012WO2012058276A3 Methods and materials for reducing mutiple risk factors associated with the metabolic syndrom
07/12/2012WO2012057492A9 Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof
07/12/2012WO2012048204A3 Prodrugs utilizing a transporter directed uptake mechanism
07/12/2012WO2012042467A3 A magnetic hybrid hydrogel
07/12/2012WO2012040331A3 Multistage nanoparticles
07/12/2012WO2012028922A3 Controlled release pharmaceutical compositions of milnacipran
07/12/2012WO2012027398A3 Compositions, methods, and systems relating to controlled crystallization and/or nucleation of molecular species
07/12/2012WO2012021791A3 Aqueous formulation with improved stability
07/12/2012WO2012007758A3 Pharmaceutical formulations
07/12/2012WO2012005709A3 Pharmaceutical composition comprising valsartan
07/12/2012WO2011154724A3 Injectable flowable composition comprising buprenorphine
07/12/2012WO2011128632A3 Gelled pharmaceutical composition
07/12/2012WO2011127151A3 Combinations of preservatives for ophthalmic compositions
07/12/2012WO2011060290A8 Immediate release tablet formulations
07/12/2012WO2011049706A8 Orally transformable tablets
07/12/2012US20120179090 Transmucosal delivery of therapeutic agents and methods of use thereof
07/12/2012US20120178808 Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
07/12/2012US20120178793 Nucleotide-cochleate compositions and methods of use
1 ... 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 ... 2991